Trials / Completed
CompletedNCT04975295
A Study of LY3361237 in Participants With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3361237 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2021-07-27
- Primary completion
- 2022-11-29
- Completion
- 2022-11-29
- First posted
- 2021-07-23
- Last updated
- 2022-12-05
Locations
7 sites across 4 countries: Bulgaria, Hungary, Poland, Slovakia
Source: ClinicalTrials.gov record NCT04975295. Inclusion in this directory is not an endorsement.